Liu JK (2014) The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Ann Med Surg (Lond) 3(4):113–116. https://doi.org/10.1016/j.amsu.2014.09.001

Article  PubMed  Google Scholar 

Paoloni M, Khanna C (2008) Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8(2):147–156. https://doi.org/10.1038/nrc2273

Article  CAS  PubMed  Google Scholar 

LeBlanc AK, Mazcko CN (2020) Improving human cancer therapy through the evaluation of pet dogs. Nat Rev Cancer 20(12):727–742. https://doi.org/10.1038/s41568-020-0297-3

Article  CAS  PubMed  Google Scholar 

Bustamante-Córdova L, Melgoza-González EA, Hernández J (2018) Recombinant antibodies in veterinary medicine: an update. Front Vet Sci 5:175. https://doi.org/10.3389/fvets.2018.00175

Article  PubMed  PubMed Central  Google Scholar 

DuBourdieu D (2019) Colostrum antibodies, egg antibodies and monoclonal antibodies providing passive immunity for animals. In: Gupta RC, Srivastava A, Lall R (eds) Nutraceuticals in veterinary medicine. Springer, Cham, pp 245–257

Chapter  Google Scholar 

Enomoto M et al (2019) Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats. Vet Rec 184(1):23–23. https://doi.org/10.1136/vr.104590

Article  PubMed  Google Scholar 

Gruen ME et al (2021) Frunevetmab, a felinized anti-nerve growth factor monoclonal antibody, for the treatment of pain from osteoarthritis in cats. J Vet Intern Med 35(6):2752–2762. https://doi.org/10.1111/jvim.16291

Article  PubMed  PubMed Central  Google Scholar 

Souza CP et al (2018) A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA. Vet Dermatol 29(6):489-e164. https://doi.org/10.1111/vde.12682

Article  PubMed  Google Scholar 

Gruen ME, Myers JAE, Lascelles BDX (2021) Efficacy and safety of an anti-nerve growth factor antibody (Frunevetmab) for the treatment of degenerative joint disease-associated chronic pain in cats: a multisite pilot field study. Front Vet Sci 8:610028. https://doi.org/10.3389/fvets.2021.610028

Article  PubMed  PubMed Central  Google Scholar 

Moyaert H et al (2017) A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis. Vet Dermatol 28(6):593-e145. https://doi.org/10.1111/vde.12478

Article  PubMed  Google Scholar 

Choi JW et al (2020) Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function. PLoS ONE 15(7):e0235518. https://doi.org/10.1371/journal.pone.0235518

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maekawa N et al (2022) Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy. Sci Rep 12(1):9265. https://doi.org/10.1038/s41598-022-13484-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Igase M et al (2022) Long-term survival of dogs with stage 4 oral malignant melanoma treated with anti-canine PD-1 therapeutic antibody: A follow-up case report. Vet Comp Oncol 20(4):901–905. https://doi.org/10.1111/vco.12829

Article  PubMed  Google Scholar 

Rue SM et al (2015) Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma. Vet Immunol Immunopathol 164(3–4):148–159. https://doi.org/10.1016/j.vetimm.2015.02.004

Article  CAS  PubMed  Google Scholar 

Mizuno T et al (2020) Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment. Sci Rep 10(1):11476. https://doi.org/10.1038/s41598-020-68470-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kamoto S et al (2020) Phase I/II clinical trial of the anti-podoplanin monoclonal antibody therapy in dogs with malignant melanoma. Cells 9(11):2529

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haran KP et al (2020) Generation and validation of an antibody to canine CD19 for diagnostic and future therapeutic purposes. Vet Pathol 57(2):241–252. https://doi.org/10.1177/0300985819900352

Article  CAS  PubMed  Google Scholar 

Howland D et al (2020) Large animal models of Huntington’s disease: what we have learned and where we need to go next. J Huntingtons Dis 9(3):201–216. https://doi.org/10.3233/jhd-200425

Article  PubMed  PubMed Central  Google Scholar 

Pinnapureddy AR et al (2015) Large animal models of rare genetic disorders: sheep as phenotypically relevant models of human genetic disease. Orphanet J Rare Dis 10(1):107. https://doi.org/10.1186/s13023-015-0327-5

Article  PubMed  PubMed Central  Google Scholar 

Banstola A, Reynolds JNJ (2022) The sheep as a large animal model for the investigation and treatment of human disorders. Biology 11(9):1251

Article  PubMed  PubMed Central  Google Scholar 

Spannbauer A et al (2019) Large animal models of heart failure with reduced ejection fraction (HFrEF). Front Cardiovasc Med. https://doi.org/10.3389/fcvm.2019.00117

Article  PubMed  PubMed Central  Google Scholar 

Pallotti S et al (2022) Dog–human translational genomics: state of the art and genomic resources. J Appl Genet 63(4):703–716. https://doi.org/10.1007/s13353-022-00721-z

Article  PubMed  Google Scholar 

Zhao J, Cao Y, Jusko WJ (2015) Across-species scaling of monoclonal antibody pharmacokinetics using a minimal PBPK model. Pharm Res 32(10):3269–3281. https://doi.org/10.1007/s11095-015-1703-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li M et al (2019) A new model to describe the single-dose pharmacokinetics of bevacizumab and predict its multiple-dose pharmacokinetics in beagle dogs. Iran J Pharm Res 18(3):1147–1155. https://doi.org/10.22037/ijpr.2019.1100716

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah DK, Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39(1):67–86. https://doi.org/10.1007/s10928-011-9232-2

Article  CAS  PubMed  Google Scholar 

Bussing D, Shah DK (2020) Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits. J Pharmacokinet Pharmacodyn 47(6):597–612. https://doi.org/10.1007/s10928-020-09713-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gearing DP et al (2013) A fully caninised anti-NGF monoclonal antibody for pain relief in dogs. BMC Vet Res 9(1):226. https://doi.org/10.1186/1746-6148-9-226

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tabrizi M et al (2019) Pharmacokinetic properties of humanized IgG1 and IgG4 antibodies in preclinical species: translational evaluation. AAPS J. https://doi.org/10.1208/s12248-019-0304-3

Article  PubMed  Google Scholar 

Gearing DP et al (2016) In vitro and in vivo characterization of a fully felinized therapeutic anti-nerve growth factor monoclonal antibody for the treatment of pain in cats. J Vet Intern Med 30(4):1129–1137. https://doi.org/10.1111/jvim.13985

Article  CAS  PubMed  PubMed Central  Google Scholar 

Walters RR, Boucher JF, De Toni F (2021) Pharmacokinetics and immunogenicity of frunevetmab in osteoarthritic cats following intravenous and subcutaneous administration. Front Vet Sci. https://doi.org/10.3389/fvets.2021.687448

Article  PubMed  PubMed Central  Google Scholar 

Lee C et al (2020) Deriving a dose and regimen for anti-glucosaminidase antibody passive-immunisation for patients with Staphylococcus aureus osteomyelitis. Eur Cells Mater 39:96–107. https://doi.org/10.22203/ecm.v039a06

Article  CAS  Google Scholar 

Fieux M et al (2021) FcRn as a transporter for nasal delivery of biologics: a systematic review. Int J Mol Sci 22(12):6475

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown RP et al (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13(4):407–484. https://doi.org/10.1177/074823379701300401

Article  CAS  PubMed  Google Scholar 

Campbell JL Jr et al (2021) Integration of paraquat pharmacokinetic data across species using PBPK modelling. Toxicol Appl Pharmacol 417:115462. https://doi.org/10.1016/j.taap.2021.115462

Article  CAS  PubMed  Google Scholar 

Chen Y et al (2016) Prediction of deoxypodophyllotoxin disposition in mouse, rat, monkey, and dog by physiologically based pharmacokinetic model and the extrapolation to human. Front Pharmacol 7:488–488.